Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model
about
Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.Epidemiology of antimicrobial resistance in bloodstream infections.A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.When sepsis persists: a review of MRSA bacteraemia salvage therapy.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity
P2860
Q35678198-2BE9A84A-35CD-495D-9C08-6DA1A1FD08FFQ36364106-D43559D8-EE31-4C65-ACA8-31FB4BD270CDQ36439072-66111A7B-2931-449C-AB75-31C188AEF49BQ36565462-C39B8AC4-1713-4E66-84B3-4A72619F4080Q36882486-61A28AF3-9A70-4D22-919D-5F59A0296C00Q36913239-C644C665-C8FE-4B2A-B464-8644FDED5FF8Q38530316-8B9BC743-378C-4E3E-8E74-E1AB8C6ED5B9Q38632488-3DC8A3BB-00FC-4F69-ACAC-793EC67771BCQ38892614-2DD50BE6-086B-4A51-B093-65471E00D8C7Q38895642-6AE45A2A-07CD-47A0-97AF-F2647E684721Q39267105-23F9C05C-1C07-48D3-94C3-8FAC8FEC9D5FQ41172790-05BF23E0-439F-4EAB-A7EE-157986EC0E50Q41687426-A6B8B4BD-5646-4BB2-8D66-71F488AF4B82Q42696736-8247BE1D-6931-45FB-B457-E7006A78DC02
P2860
Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of telavancin activ ...... okinetic/pharmacodynamic model
@en
type
label
Evaluation of telavancin activ ...... okinetic/pharmacodynamic model
@en
prefLabel
Evaluation of telavancin activ ...... okinetic/pharmacodynamic model
@en
P2093
P2860
P356
P1476
Evaluation of telavancin activ ...... okinetic/pharmacodynamic model
@en
P2093
Céline Vidaillac
Michael J Rybak
Molly E Steed
P2860
P304
P356
10.1128/AAC.05849-11
P407
P577
2011-11-28T00:00:00Z